Clinical Trial Detail

NCT ID NCT02362048
Title ACP-196 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Pancreatic Cancer
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Acerta Pharma BV
Indications

pancreatic ductal adenocarcinoma

Therapies

Acalabrutinib

Pembrolizumab

Age Groups: adult

No variant requirements are available.